OMO-1 is an oral, highly selective small molecule MET kinase inhibitor, that has demonstrated potent single agent and combination activity in a range of preclinical cancer models.
OMO-2 is a dual MET and RAS pathway inhibitor under pre-clinical investigation as a targeted therapy for lung cancer, as well as potential broader oncology applications when used in combination with EGFR inhibitors.
For more information please contact: OCTIMET Oncology NV Shelley Margetson, CEO Email: Pieter Van Reysschootlaan 2/104 9051 Sint-Denijs-Westrem (Gent) Belgium